Categories: HealthcareNews

Nemaura Medical to Present at the Sidoti & Co. Micro Cap Virtual Conference

Loughborough, England, Jan. 11, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle and weight reduction programs, announces that CEO Dr. Faz Chowdhury will present a corporate overview at the Sidoti & Co. Micro Cap Virtual Conference being held on January 18 -19, 2023.

Presentation Date: January 19, 2023
Time: 9:15am EST
Webcast Link below:
https://sidoti.zoom.us/webinar/register/WN_QP9bg_5URLi959aJZBubUw

Dr. Chowdhury will be available for one-on-one investor meetings throughout the conference. Investors can attend the conference and request a meeting with Dr. Chowdhury by registering for the conference using the link below:
January 2023 Presenting Company Registration

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently also commercializing sugarBEAT® and proBEAT. sugarBEAT®, a CE mark approved Class IIb medical device, as a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence under a digital healthcare subscription service that has been launched in the U.S. as a general wellness product as part of its BEAT® diabetes program that is currently undergoing pilot studies.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Media Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

Investor Contact:
Bret Shapiro – Senior Managing Partner
CORE IR
561-479-8566
brets@coreir.com

Staff

Recent Posts

Restart Life Sciences Signs Binding LOI to Acquire The Holy Crap Foods Portfolio of Brands and Manufacturing Plant

Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

15 minutes ago

Functional Brands Inc. Launches Kirkman’s(R) Skin, Beauty & Anti-Aging Bundle: A Science-Backed Approach to Radiant, Resilient Skin

Comprehensive Formula Featuring Reduced Glutathione, Zinc Cream, Biotin, and Grapefruit Seed ExtractLake Oswego, Oregon--(Newsfile Corp.…

15 minutes ago

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities

Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces…

1 hour ago

XRP Healthcare® Secures Global Trademark Protection at the Intersection of Healthcare Services and XRP-Powered Payments

Multi-jurisdiction trademark coverage reinforces XRP Healthcare's position across digital health, pharmacy networks, and XRP-based payment…

2 hours ago

Black Book Poll: “Governed AI” Emerges as the Deciding Factor in 2026 NHS Procurement

Respondents report approvals and evaluation readiness are now the bottlenecks driving demand for reusable safety…

2 hours ago

Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares

LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the…

2 hours ago